After finishing at $19.61 in the prior trading day, Privia Health Group Inc (NASDAQ: PRVA) closed at $19.09, down -2.65%. In other words, the price has decreased by -$0.52 from its previous closing price. On the day, 594750 shares were traded. PRVA stock price reached its highest trading level at $19.86 during the session, while it also had its lowest trading level at $19.04.
Ratios:
Our goal is to gain a better understanding of PRVA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.06. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on March 06, 2024, initiated with a Equal Weight rating and assigned the stock a target price of $22.
BofA Securities Downgraded its Buy to Neutral on February 22, 2024, while the target price for the stock was maintained at $21.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Sullivan William M sold 400 shares for $23.02 per share. The transaction valued at 9,208 led to the insider holds 5,445,018 shares of the business.
Sullivan William M sold 7,115 shares of PRVA for $163,858 on Mar 08 ’24. The Director now owns 5,445,418 shares after completing the transaction at $23.03 per share. On Jan 25 ’24, another insider, Sullivan William M, who serves as the Director of the company, sold 12,000 shares for $23.13 each. As a result, the insider received 277,560 and left with 5,452,533 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRVA now has a Market Capitalization of 2.32B and an Enterprise Value of 1.94B. As of this moment, Privia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 103.08, and their Forward P/E ratio for the next fiscal year is 57.57. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.37 while its Price-to-Book (P/B) ratio in mrq is 4.02. Its current Enterprise Value per Revenue stands at 1.17 whereas that against EBITDA is 71.43.
Stock Price History:
Over the past 52 weeks, PRVA has reached a high of $30.15, while it has fallen to a 52-week low of $19.17. The 50-Day Moving Average of the stock is 21.03, while the 200-Day Moving Average is calculated to be 23.33.
Shares Statistics:
The stock has traded on average 957.39K shares per day over the past 3-months and 787.15k shares per day over the last 10 days, according to various share statistics. A total of 118.22M shares are outstanding, with a floating share count of 101.95M. Insiders hold about 14.02% of the company’s shares, while institutions hold 96.00% stake in the company. Shares short for PRVA as of Feb 29, 2024 were 7.57M with a Short Ratio of 7.91, compared to 7.21M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.39% and a Short% of Float of 11.80%.
Earnings Estimates
Its stock is currently analyzed by 14 different market analysts. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.07 and a low estimate of $0.03, while EPS last year was $0.06. The consensus estimate for the next quarter is $0.06, with high estimates of $0.09 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.33 and $0.17 for the fiscal current year, implying an average EPS of $0.24. EPS for the following year is $0.33, with 14 analysts recommending between $0.4 and $0.23.
Revenue Estimates
9 analysts predict $681.7M in revenue for the current quarter. It ranges from a high estimate of $700M to a low estimate of $652.3M. As of the current estimate, Privia Health Group Inc’s year-ago sales were $658.9M, an estimated increase of 3.50% from the year-ago figure.
A total of 9 analysts have provided revenue estimates for PRVA’s current fiscal year. The highest revenue estimate was $2.89B, while the lowest revenue estimate was $2.81B, resulting in an average revenue estimate of $2.84B. In the same quarter a year ago, actual revenue was $2.84B, up 0.10% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $3.25B in the next fiscal year. The high estimate is $3.51B and the low estimate is $3.15B. The average revenue growth estimate for next year is up 14.60% from the average revenue estimate for this year.
